ROCKVILLE, MD , April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for

ROCKVILLE, MD , Feb. 26, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

MARGENZA™ approved in December 2020 ; commercial launch expected March 2021 July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab Multiple clinical updates across portfolio anticipated in 2021 Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md.

ROCKVILLE, MD , Feb. 18, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien,

ROCKVILLE, MD , Feb. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved

ROCKVILLE, MD , Feb. 08, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb)   showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® ( trastuzumab), both with chemotherapy In the U.S. , MARGENZA is approved, in combination with chemotherapy, for the treatment of

ROCKVILLE, MD , Jan. 11, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate

PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study ROCKVILLE, MD , Dec. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc.  (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based

ROCKVILLE, MD , Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of

53.8% ORR in relapsed/refractory DLBCL patients  Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date  ROCKVILLE, MD , Dec. 07, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD , Dec. 06, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing

MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL , Nov.

ROCKVILLE, MD , Nov. 30, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in milestones have

ROCKVILLE, MD , Nov. 09, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,

ROCKVILLE, MD , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinical abstracts

ROCKVILLE, MD , Oct. 28, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its

— Role of TP53 abnormalities in immunotherapy response in AML highlighted ROCKVILLE, MD , Oct. 15, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the

Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD , Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical

ROCKVILLE, MD , Sept. 22, 2020 (GLOBE NEWSWIRE) --   MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in

$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD , Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based

MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 2020  ROCKVILLE, MD ,